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Abstract
Recent investigations have found a higher incidence of adverse events associated with 
hematopoietic cell donation in related donors (RDs) who have morbidities that if present in an 
unrelated donor (UD) would preclude donation. In the UD setting, regulatory standards ensure 
independent assessment of donors, one of several crucial measures to safeguard donor health and 
safety. A survey conducted by the Center for International Blood and Marrow Transplant 
Research (CIBMTR) Donor Health and Safety Working Committee in 2007 reported a potential 
conflict of interest in >70% US centers, where physicians had simultaneous responsibility for RDs 
and their recipients. Consequently, several international organizations have endeavored to improve 
practice through regulations and consensus recommendations. We hypothesized that the changes 
in the 2012 FACT-JACIE Standards, resulting from the CIBMTR study, will have significantly 
impacted practice. Accordingly, a follow-up survey of US transplant centers was conducted to 
assess practice changes since 2007, and investigate additional areas where RD care was predicted 
to differ from UD care. 73 centers (53%), performing 79% of US RD transplants responded. 
Significant improvements were observed since the earlier survey; 62% centers now ensure 
separation of RD and recipient care (P<0.0001). However, this study identifies several areas 
where RD management does not meet international donor care standards. Particular concerns 
include counseling and assessment of donors before HLA typing, with 61% centers first disclosing 
donor HLA results to an individual other than the donor, the use of unlicensed mobilization 
agents, and the absence of long-term donor follow-up. Recommendations for improvement are 
described.
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The importance of independent assessment of hematopoietic or solid organ donors to 
prevent real or perceived coercion of an individual who is undergoing a procedure from 
which they have no medical gain has been widely discussed1-6. The practice of a physician 
simultaneously managing both a hematopoietic cell (HPC) donor and their transplant 
recipient is prevented by National Marrow Donor Program (NMDP) and World Marrow 
Donor Association (WMDA) regulatory policies7,8 in the unrelated donor (UD) setting,8,9 as 
well as in solid organ transplantation.2 However, similar regulatory policies covering adult 
related donors (RDs) for HPC transplantation do not exist.
In 2007, the Donor Health and Safety Working Committee of the Center for International 
Blood and Marrow Transplant Research (CIBMTR) conducted a survey investigating 
practice patterns in RD care in US transplant centers.10 This study highlighted a potential 
conflict of interest in >70% of centers, where a physician would routinely have simultaneous 
responsibility for a HPC transplant recipient and their RD.
An earlier survey of delegates at the European Group for Blood and Marrow Transplantation 
(EBMT) annual meeting 2005, demonstrated similar practices in European centers, with 
only 25% respondents indicating that care of RDs was provided by clinicians who were not 
involved in the care of their transplant recipients.11 Both this group, and a subsequent study 
of Italian apheresis centers,12 illustrated further issues with the lack of standardized 
guidelines and screening procedures for RDs.
At the time of these early surveys, Foundation for the Accreditation of Cellular Therapy and 
the Joint Accreditation Committee – ISCT and EBMT (FACT-JACIE) Standards13 did not 
specifically require transplant centers to separate the care of a RD and their recipient. 
Following investigations showing a higher incidence of adverse events, including death, in 
RDs compared to UDs,14 and consensus recommendations heightening awareness around 
donor care practices, a specific recommendation addressing independent evaluation of RDs 
was introduced to 5th Edition of FACT-JACIE standards13 in March 2012.
Recommendations on family donor management15 from a subgroup of the Ethics Working 
Group and the Clinical Working Group of the WMDA are still more definitive, suggesting 
that family donors should be assessed by a practitioner “who is not directly involved in the 
recipient's care”. This latter publication also emphasized the importance of donor health 
assessment prior to tissue typing, and made recommendations for donor follow up to be in 
line with that of UDs. Donor follow up recommendations have subsequently been endorsed 
by a Worldwide Network for Blood and Marrow Transplantation (WBMT) consensus paper 
in 2013.16
We hypothesized that the changes to FACT-JACIE standards, in conjunction with other 
initiatives, will have significantly impacted practice patterns in US transplant centers. In 
order to test our hypothesis, we conducted a follow-up survey. In addition to investigating 
whether improvements have occurred in the areas addressed in the earlier survey, we took 
this opportunity to examine practice at other stages of the donor care pathway where we 
hypothesized RD care may differ from standard practice in the UD setting.
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A 38-item survey was developed to examine related donor care practice (see Supplemental 
Appendix). The survey contained identical questions to the earlier survey in order to allow 
direct comparison between eras, as well as new questions to address the areas of care not 
previously examined. The survey was administered as an internet-based questionnaire via a 
secure hyperlink (surveymonkey.com) from August to November 2014.Program directors of 
all US allogeneic transplant centers reporting data to CIBMTR, and all European allogeneic 
transplant centers reporting data to EBMT received an email invitation to participate with a 
request to forward the survey to the physician responsible for RD care. Entry into a drawing 
for a free Tandem Annual Meeting registration was offered as an incentive to increase the 
response rate. All procedures were approved by the National Marrow Donor Program 
(NMDP) Institutional Review Board.
Due to differences in practice, the results from CIBMTR and EBMT centers were analyzed 
separately. The CIBMTR center data is presented in this manuscript.
The survey invitation specified that the study referred to the care of adult related HPC 
donors only, and the survey terminated if respondents answered ‘no’ to the first question 
“Does your center perform allogeneic HPC transplants from adult (≥18 years old) related 
donors?”.
Following the initial invitation, non-responders received three further email reminders. If >1 
response was received from a center, the most complete was used for analysis.
US centers were grouped by size in the analysis, defined as the number of allografts per 
year, as reported to CIBMTR (2011-2012). Centers were also grouped as previously10 
according to their geographic location by US regions including: New England (ME, NH, 
VT, MA, RI, CT), Mid-Atlantic (NY, NJ, PA), South Atlantic (DE, MD, DC, VA, WV, NC, 
SC, GA, FL), East North Central (OH, IN, IL, MI, WI), East South Central (KY, TN, AL, 
MS), West North Central (MN, IA, MO, ND, SD, NE, KS), West South Central (AR, LA, 
OK, TX), Mountain (MT, ID, WY, CO, NM, AZ, UT, NV); and Pacific (WA, OR, CA, AK, 
HI).
Participants were able to skip questions they were unwilling/unable to answer, however 
results were only analyzed and presented for questions that >80% of responding centers had 
completed. Statistics were performed using SPSS software (version 22.0; SPSS, Chicago, 
IL). Relationships between categorical center characteristics and response rate or adherence 
to standards were examined using Chi squared or Fisher's exact test where appropriate.
Results
Response rate
Excluding duplicates, 73 responses from 139 eligible centers in the US were received, 
giving an overall response rate of 53%. All responding centers confirmed that they 
performed allogeneic transplants using RD aged ≥18 years. Responding centers performed 
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>80% of total allogeneic hematopoietic cell transplants (HCTs) and 79% of the total related 
donor HCTs reported to CIBMTR (2011-2012).
As found in the 2007 survey, centers with higher transplant volume were more likely to 
respond to the survey (shown in Figure 1A); 67% of non-responding centers performed < 30 
allografts per year, compared to 22% of responding centers (P<0.0001). As shown in Figure 
2B, the response rate did not vary significantly by US region (P=0.47), with similar response 
patterns to the earlier survey.
A higher response rate was seen in FACT accredited centers; 70/109 (64%) accredited 
versus 3/30 (10%) non-accredited centers responded (P<0.001), and >95% responding 
centers were FACT accredited. Responses were received from 59% of NMDP transplant 
centers, however no responses were received from the 20 transplant centers not affiliated 
with NMDP.
The characteristics of responding centers are summarized in Table 1.
Healthcare providers involved in donor care
We compared findings regarding providers of donor care from the current (2014) survey 
with the earlier survey conducted in 200710 and found no change in the professional 
background of the healthcare providers responsible for donor clearance between eras (Figure 
2A), with transplant physicians remaining responsible for donor clearance in almost 80% of 
centers. Despite this, we found a highly significant improvement with respect to separation 
of donor and recipient care over the seven years between surveys. As indicated in Figure 1B, 
62% of centers now ensure separation of recipient and donor care (with the person providing 
clearance either being uninvolved in the transplant program or being affiliated with the 
transplant team but not involved in recipient care), an increase from 23% in the previous 
survey. In just 7% of centers the physician responsible for donor clearance routinely has 
responsibility for the transplant recipient (reduced from 32% centers in 2007), and in 30% of 
centers this physician responsible for donor clearance may be involved in the care of the 
transplant recipient (a reduction from 42% centers in 2007); P<0.0001. We investigated how 
other aspects of donor care, not previously studied, were provided, and found that bone 
marrow harvests were almost exclusively performed by transplant physicians (96%), who in 
half of these centers were members of the team caring for the recipient. Transplant 
physicians were responsible for RD apheresis procedures in 50% of centers.
Care of potential donors prior to HLA typing
We found substantial center variation in most aspects of care received by RDs at the point of 
initial HLA typing (summarized in Table 2), with practice differing from that of potential 
UDs in most cases. The process for informing RDs prior to HLA typing consisted solely of a 
verbal discussion without written information in almost half of centers, with no verification 
of willingness to proceed with donation in 25% of centers. 30% of centers do not make any 
assessment of donor health prior to determining RD matching status, and only a small 
proportion (17%) undertake a formal health history questionnaire at this point.
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The disclosure of donor HLA typing results also varied by center, with a quarter of centers 
stating that the transplant recipient was the first individual to be informed of the potential 
RD's matching status. An additional 17% of centers disclosed results to the referring 
physician first, 19% had no consistent practice and only 39% stated that the donor would 
always be told first.
Donor care policies and harvesting procedures
In some areas (largely those covered in FACT-JACIE Standards) a near-uniform existence 
of RD care policies was seen. All responding centers reported that they had a written policy 
or Standard Operating Procedure for RD care, and 94% had a process for credentialing 
physicians performing bone marrow (BM) harvests. 93% of centers used defined eligibility 
criteria to assess adult RDs, which in 55% of centers were based on NMDP criteria. 90% of 
centers also followed UD practice in using a written health questionnaire as part of the donor 
medical assessment.
In other aspects of care where clear policies exist for UDs, we found the presence of 
equivalent policies for RDs in US transplant centers to be less prevalent (shown in Table 2). 
More than 50% of centers did not have a limit for the number of apheresis procedures a 
donor could undergo during their initial donation, and, somewhat surprisingly, 29% of 
centers had used plerixafor off-label for RD mobilization outside the context of a clinical 
trial. 68% of centers had a limit for aspirated BM harvest volume, most commonly 
20mls/kg, with only one center specifying a limit exceeding NMDP policy for UD marrow 
harvests.
Donor follow-up
As shown in Figure 3, >90% of centers provided short-term follow up at one week post 
donation, usually by telephone, however in only 14% of centers did duration of follow up 
extend up to a year, and no centers followed up RDs beyond one year.
The impact of center volume
We compared the lower volume centers (performing fewer than the median 25 RD HCTs 
per year) to higher volume centers, and found that RD marrow harvests were more likely to 
be performed by the same transplant physicians caring for the recipient in lower volume 
centers (70% versus 38%; P=0.009). A trend was also seen towards the lower volume 
centers being less likely to have a policy defining the limit for BM volume aspirated at 
harvest, a policy present in 57% lower volume versus 79% higher volume centers 
(P=0.077). Center volume did not impact any other areas of related donor practice studied.
Discussion
A major concern in RD care to date has been around the conflict of interest where the same 
physician may be responsible for a donor and their recipient, a practice which occurred in 
>70% of US centers in the 2007 survey10. We report a significant improvement in this 
survey, with only 7% of centers now routinely allowing a physician to be responsible for 
medical clearance of a RD while caring for their recipient, (with a further 32% indicating 
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that care may overlap). This demonstrates the power of practice-based surveys to identify 
areas of concern and drive innovations through awareness and engagement of the 
community.
This study provides important insights into aspects of RD care, which have not been 
previously evaluated in the US. Since responding centers were responsible for the care of 
approximately 80% of adult RDs, we believe these results are likely to be representative of 
the care received by the majority of RDs. Due to a very low response rate among small 
volume centers performing <30 allografts per year, and those which lack FACT 
accreditation or NMDP affiliation, the results cannot necessarily be generalized to these 
centers. We also acknowledge that despite requesting that the most appropriate specialist 
complete the survey, we cannot verify that this person was familiar with all areas of donor 
care in their center.
We found practice to be largely compliant with most FACT requirements, including the 
existence of a policy for RD care, written donor eligibility criteria and a credentialing 
process for physicians performing BM harvests. The notable exception was donor follow up, 
where, despite an explicit FACT requirement for systematic RD follow up, and international 
recommendations suggesting 10 year follow up for all donors,16 long-term RD follow-up in 
the US is universally absent. Although reassuring data from large studies of UDs report no 
increase in malignancies or autoimmune disease in peripheral blood stem cell (PBSC) 
donors compared to the general population,17-19 RDs are generally older than UDs, have 
more health issues, and are more likely to experience adverse events.20-22 Furthermore, we 
found that almost 30% of centers had used off-label plerixafor to mobilize RDs outside the 
clinical trial context. At present minimal data are available regarding the long-term effects 
of alternative mobilization agents in normal donors (e.g. plerixafor), and ongoing 
surveillance will be essential to establish the safety of such agents and exclude long-term ill 
effects on donor health. A proportion of RDs may also experience psychological difficulties 
as a consequence of donation (particularly if the recipient dies or develops graft versus host 
disease).23
Although RD follow-up recommendations to date have focused on excluding late health 
complications associated with donation, there may also be a need to incorporate 
psychological support for RDs into follow-up programs.
In areas of care that have not yet been addressed by current FACT-JACIE standards, but 
where World Marrow Donor Association Standards for UD practice provide a benchmark, 
practice was heterogeneous, and generally fell below UD norms. Perhaps the greatest 
concern identified in this study relates to the care of potential donors at the stage of HLA 
typing. The duty of care to a related donor starts at the point of contact, and counseling 
before HLA typing is essential to identify both reluctance about donation, and health issues 
that would preclude donation, to allow early deferral of unwilling or unfit donors as well as 
reducing unnecessary costs of HLA typing. Failing to defer prior to HLA typing is 
problematic for a number of reasons. Firstly, a formal donor medical assessment is 
frequently performed shortly before the planned donation date (often within 30 days, to 
obviate the need for repeat virology testing); if a donor is found to be unsuitable and 
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cancelled at this point, the transplant is almost invariably delayed while an alternative donor 
is found. Secondly, donors may experience distress and guilt if they are deferred once they 
are found to be a match, particularly since many exclusion criteria are, to a degree, lifestyle 
associated. It is possible that donors may even minimize their own health issues for fear of 
jeopardizing the treatment of their sick relative if they do not donate.
Additional issues can occur when the transplant recipient is informed about their matching 
status before the donor, a situation that occurred in a quarter of responding centers, with no 
consistent practice in a further 19%. This denies the donor the choice of declining to donate 
without potential consequences for the relationship with their relative, and may pressurize 
them to proceed. Improving practice in these early stages of donor care, should not require 
additional financial resources, and can in fact save costs. Hence we encourage healthcare 
providers involved in RD care to consider reviewing their early donor counseling practice. 
We also suggest that where possible formal donor medical assessments should be conducted 
far enough in advance of the donation that medical issues requiring further investigation or 
treatment prior to donation can be addressed. We have demonstrated the efficacy of FACT/
JACIE standards in advancing RD care and hope to see further improvements following the 
introduction of 6th Edition FACT-JACIE Standards in June 2015 which mandate that the 
allogeneic donor must consent for release before their health or HLA typing results can be 
disclosed to recipient or the recipient's physician. We also hope to see further improvements 
in separation of RD and recipient care following the introduction of the requirement that 
informed consent and donor evaluation must be obtained by a health care professional who 
is not the primary health care professional overseeing care of the recipient (this was only a 
recommendation in the 5th edition). We encourage registries to create and share further 
information resources with transplant centers to aid donor counseling and assessment. This 
already occurs to some extent (for example a few centers supplied RDs with written 
information sourced from NMDP, and many centers base their RD eligibility criteria on 
NMDP UD criteria) but could be extended to include standardized health assessment and 
information tools, or education resources to train persons involved in the evaluation of RDs.
It is important to recognize that in some areas ‘optimal’ care is nearly impossible to achieve 
with current transplant center staffing models. For example, in an ideal world, BM 
harvesting of a donor should not be performed by the physician caring for the recipient; 
however the number of BM harvests has declined, and it is already difficult for operators to 
achieve sufficient experience resulting in declining harvest quality over time.24 Expertise in 
this procedure is crucial to achieve a good quality harvest ensuring a good cell dose for the 
recipient, whilst protecting the donor by avoiding a large volume harvest. In small centers 
where very few specialists can maintain competence in this procedure, avoiding overlap of 
care may be difficult, therefore policies defining limits for marrow aspiration volumes and 
procedure duration are essential to ensure standardized practice.
This study focused on determining current practice patterns. A critical next step will be to 
determine the opinions of the physicians delivering donor care regarding the perceived need 
for change and barriers to improving practice. For example, we suspect that the major 
obstacles to providing RD follow-up are logistical and financial constraints, but defining 
these more thoroughly is necessary before exploring potential solutions. In a similar manner 
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it was beyond the scope of this study to evaluate the precise RD eligibility criteria used by 
transplant centers, but it would be useful to determine how closely these mirror UD 
eligibility criteria. The WBMT have recently published consensus statements regarding 
suitability criteria for adult related donors25 and determination of eligibility in pediatric 
related donors26 which we hope will help centers move towards using uniform deferral 
criteria. Over the last 10 years, the use of haploidentical donors has dramatically increased 
in US transplant centers, raising questions around the capacity of transplant centers dealing 
with the increased RD workload. Additional approaches to the RD assessment may also be 
necessary since the dynamics of a son/daughter to their parent or a parent to their child are 
different to those between siblings.27 Pediatric donor practice was not addressed in this 
study due to different regulatory requirements for minor donors; few if any studies have 
directly investigated pediatric donor practice, and a similar study addressing this gap would 
be timely.
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Significant improvements in RD care following JACIE-FACT Standards in this area
Despite specific recommendations, long-term related donor follow-up remains 
absent
Practice regarding the disclosure of donor HLA results is concerning
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Figure 1. Characteristics of responding and non-responding centers
(A) Percentage of centers that responded to the survey in each category of center volume 
(number of allogeneic hematopoietic cell transplants performed each year) (B) Distribution 
of responding and non responding transplant centers by geographic region: NE indicates, 
New England; Mid-Atl, Mid-Atlantic; S-Atl, South Atlantic; ENC, East North Central; ESC, 
East South Central; West North Central; WSC, West South Central; Mtn, Mountain and Pac, 
Pacific
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Figure 2. Providers responsible for donor care in the 2007 and 2014 surveys
(A) Professional background of the provider responsible for donor clearance. (B) 
Involvement of donor's provider in care of the recipient.
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Figure 3. Related donor follow-up
The duration of donor follow up offered and the method by which follow up is provided.
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Table 1
Characteristics of responding centers.
Responding centers (n = 73)
Median related donor allografts per year (range) 25 (1-167)




71 or more 7 (10)
Median total allografts per year (range) 63 (1-397)





300 or more 3 (4)
NMDP-affiliated transplantation center n (%) 73 (100)
FACT accredited center, n (%) 70 (96)
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Table 2
Responses regarding the care of related donors
Number of centers
Healthcare provider making initial contact prior to HLA-typing
Transplant physician 6 (8%)
Other Physician 4 (5%)
Transplant Specialist Nurse 45 (62%)
Other nurse 8 (11%)
Non-clinical Admin 10 (14%)
Information supplied to donors pre HLA typing
Verbal only 35 (48%)
Local written information 33 (45%)
National written information 5 (7%)
RD heath assessment pre-HLA typing
By written health questionnaire 5 (7%)
Health questionnaire over phone 7 (10%)
Verbal discussion open ended questions 39 (53%)
No assessment 22 (30%)
Willingness to donate is verified pre-HLA typing 55 (75%)
Individual to whom donor HLA results are first disclosed
Donor 28 (39%)
Recipient 18 (25%)
Referring physician 12 (17%)
No consistent practice 14 (19%)
Existence of a written policy for RD care 73 (100%)
Written eligibility criteria exist for acceptance of RDs 67 (92%)
Source of donor eligibility criteria
Locally written 48(66%)
Based on NMDP criteria 40 (55%)
Based on WMDA criteria 3 (4%)
A policy defines the maximum number of apheresis procedures a donor may undergo for their initial donation 33 (45%)
Is plerixafor ever used in mobilization of RDs?
Yes 20 (29%)
No 35 (52%)
Only in the context of a clinical trial 13 (19%)
A policy defines the maximum volume aspirated at bone marrow harvest apheresis procedures a donor may undergo for 
their initial donation
44 (60%)
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Number of centers
There is a process for credentialing physicians performing BM harvests 61 (84%)
Recipients transplant team perform donor's BM harvest 39 (54%)
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